Politician trade (House)

Abbott Laboratories (ABT): Rep. Laura Friedman (CA30) disclosed an exchange $1K–$15K

Rep. Laura Friedman (CA30) disclosed an exchange of Abbott Laboratories in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
24 days
Disclosure lag
Traded
Mar 24, 2026
Disclosed
Apr 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 23, 2026Insider · First insider buy since Feb 2021CEO purchased ~$2.01M of ABT shares in the open market
  2. Jan 29, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  3. Feb 4, 2026Insider · 1 personInsiders: 2 purchases (~$1.1M)
  4. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  5. Feb 13, 2026FDAFDA device clearance: Armada™ 14 NC PTA Catheter
  6. Feb 20, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
  7. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  8. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$485K)
  9. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  10. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
  11. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000

What came next

  1. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  2. Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  3. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
  4. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
  5. Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  6. Apr 20, 2026FDAFDA device clearance: EnSite™ X EP System
  7. Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
  8. Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
  9. Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
  10. Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
  11. Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
  12. Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
  13. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  14. May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
  15. May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
  16. May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  17. May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  18. May 27, 2026Government · Federal Register noticeDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
  19. May 27, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  20. Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Rep. Laura Friedman (CA30)

The full history of Rep. Laura Friedman (CA30) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Abbott Laboratories (ABT) stock, and how much?

Rep. Laura Friedman (CA30) disclosed an exchange of Abbott Laboratories in the $1K–$15K range. Reported range, not an exact amount.

When did it happen, and when was it made public?

Traded: Mar 24, 2026. Disclosed: Apr 17, 2026. That is 24 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Abbott Laboratories recently?

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.

Does this mean ABT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data